Avience Biomedicals Limited logo

IPO details · Updated

Avience Biomedicals Limited

ClosedSMENSE: AVIENCE
Check Allotment
Price Band
₹196 – ₹208
Lot Size
600 shares
Min. Investment
₹1,24,800
Issue Size
₹30.24 Cr
Offer Dates
18 Jun – 22 Jun 2026
Listing
25 Jun 2026

Issue Details

Full details →
Total Issue Size
₹30.24 Cr
14,53,800 shares
Fresh Issue
₹30.24 Cr
14,53,800 shares
Offer for Sale
₹0 Cr
Face Value
₹10 per share
Issue Type
Book-built IPO
Listing At
NSE SME
Shares Pre-Issue
40,31,256
Shares Post-Issue
54,85,056

IPO Timeline

  1. Offer opens

    18 Jun 2026

  2. Offer closes

    22 Jun 2026

  3. Allotment

    23 Jun 2026

  4. Listing

    25 Jun 2026

Issue Allocation

Share of the offer reserved for each investor category

  • Anchor28.2%4,09,800 shares
  • QIB18.8%2,73,600 shares
  • HNI14.2%2,07,000 shares
  • Retail33.1%4,81,200 shares
  • MarketMaker5.7%82,200 shares

Subscription Status

Times subscribed by investor category

CategoryOfferedBidsSubscribed
QIB2,73,6005,38,36,272
196.77x
NII2,07,00012,36,26,610
597.23x
Retail4,81,20019,30,62,252
401.21x
Total9,61,80037,05,25,134
385.24x

Lot Size & Investment

1 lot = 600 shares

Retail (min)

2 lots · 1,200 shares

Retail (max)

2 lots · 1,200 shares

S-HNI (min)

3 lots · 1,800 shares

ApplicationLotsSharesAmount
Retail21,200₹2,49,600
Small HNI (S-HNI)31,800₹3,74,400
Big HNI (B-HNI)95,400₹11,23,200

Financial Performance

Restated figures in ₹ crore, unless stated otherwise

Financial performance by period
PeriodJan-26Mar-25Mar-24
Assets66.0756.5234.65
Total Income41.9445.9724.37
Profit After Tax5.747.232.14
EBITDA10.3411.414.08
Net Worth28.5222.786.21
Reserves & Surplus24.4918.752.93
Total Borrowing26.7322.1615.13

Key Performance Indicators

Key performance indicators
PeriodJan-06Mar-25
ROE (%)22.3850.14
ROCE (%)16.9924.84
EPS (₹)17.94
P/E (pre-issue)11.59
P/E (post-issue)16.56

About Avience Biomedicals Limited

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test. Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit. Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY. Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer. Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM). As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees Competitive Strength Strong Industry Experience and Expertise. Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits. Strong distribution network across India and is growing its international footprint. Cost-Effective and Affordable Solutions. Stringent quality control processes and complies with ISO standards and regulatory approvals.

Objects of the Issue

  • Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh (₹14.05 Cr)
  • Funding the working capital requirements of the Company (₹8.25 Cr)
  • General Corporate Purposes (₹3.97 Cr)
  • Public Issue Expenses (₹3.97 Cr)

Promoters

  • Dharam Deo Choudhary
  • Ram Nagina Choudhary
  • Janardan Pal
  • Deepa Choudhary

Company Information

Book running lead managers
  • Fintellectual Corporate Advisors Pvt.Ltd.
Registered office
C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
Market maker
Asnani Stock Broker Pvt.Ltd.

Disclaimer: Data on OpenIPO is for information only and is not investment advice. OpenIPO is not a SEBI-registered entity. GMP figures are unofficial estimates and may change. Verify all details against the company RHP and the official registrar before investing.